NCT00086710 is a Phase 1 clinical trial of Fuzeon in HIV Infections, sponsored by Trimeris.

Who is sponsoring NCT00086710?

NCT00086710 is sponsored by Trimeris.

What drugs are being tested in NCT00086710?

Interventions in NCT00086710: Fuzeon.

What condition does NCT00086710 study?

NCT00086710 studies HIV Infections, AIDS.

Is NCT00086710 still recruiting?

NCT00086710 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00086710

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration

Completed Phase 1 Last updated 23 June 2005

What this trial tests

Phase 1 trial testing Fuzeon in HIV Infections in 26 participants. Completed.

Quick facts

Lead sponsor	Trimeris
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	26
Sites	1 location across United States

Drugs / interventions tested

Fuzeon — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →
AIDS — all drugs for AIDS →

Sponsor

Trimeris — full company profile →

Who can join

Adults 18 to 64, any sex, with HIV Infections or AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00086710 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Trimeris
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00086710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing